

The effect of maternal dietary fat content and omega-6 to omega-3 ratio on offspring growth and hepatic gene expression in the rat

Journal:	<i>British Journal of Nutrition</i>
Manuscript ID	BJN-RA-19-0728.R1
Manuscript Type:	Research Article
Date Submitted by the Author:	27-Jan-2020
Complete List of Authors:	Draycott, Sally; University of Nottingham, Biosciences; The University of Adelaide, School of Agriculture, Food and Wine George, Grace; University of Nottingham, Biosciences Elmes, Matthew; University of Nottingham, Biosciences Muhlhausler, Beverly; University of Adelaide, Food and Nutrition Research Group; Commonwealth Scientific and Industrial Research Organisation, Nutrition and Health Research Langley-Evans, Simon; University of Nottingham, Biosciences
Keywords:	Maternal nutrition, Omega, Pregnancy, Growth restriction
Subject Category:	Molecular Nutrition

SCHOLARONE™
Manuscripts

1 **The effect of maternal dietary fat content and omega-6 to omega-3 ratio on offspring**
2 **growth and hepatic gene expression in the rat**

3 Sally A V Draycott^{1,2}, Grace George, Matthew J Elmes¹, Beverly S Muhlhausler^{2,3} and
4 Simon C Langley-Evans^{1*}

5 ¹ School of Biosciences, University of Nottingham, Sutton Bonington Campus,
6 Loughborough, UK

7 ² Food and Nutrition Research Group, Department of Food and Wine Science, School of
8 Agriculture Food and Wine, University of Adelaide, Adelaide, Australia

9 ³ Commonwealth Scientific and Industrial Research Organisation, Adelaide, Australia

10

11 *Corresponding author

12 Simon Langley-Evans

13 Sutton Bonington Campus

14 Sutton Bonington

15 Leicestershire

16 LE12 5RD

17 UK

18 Simon.Langley-evans@nottingham.ac.uk

19

20 Short title: Maternal diet, offspring gene expression.

21 Key words: Maternal nutrition, omega-6, omega-3, pregnancy, growth restriction

23 Abstract

24 Omega-6 fatty acids have been shown to exert pro-adipogenic effects whereas omega-3 fatty
25 acids ~~appear to~~ work in opposition. Increasing intakes of LA (linoleic acid; omega-6) vs
26 ALA (alpha-linolenic acid; omega-3) in Western diets has led to the hypothesis that
27 consumption of this diet during pregnancy may be contributing to adverse offspring health.
28 This study investigated the effects of feeding a maternal dietary LA:ALA ratio similar to that
29 of the Western diet (9:1) compared to a proposed 'ideal' ratio (~1:1.5), at two total fat levels
30 (18% vs 36% fat w/w), on growth and fat depositionlipogenic gene expression in the
31 offspring. Female Wistar rats were assigned to one of the four experimental groups
32 throughout gestation and lactation. Offspring were culled at 1 and 2 weeks of age for blood
33 and tissue sample collection. Offspring of dams consuming a high-36% fat diet were ~20%
34 lighter than those exposed to a low-18% fat diet ($P < 0.001$). Male, but not female, liver weight
35 at 1 week was ~13% heavier, and had increased glycogen ($P < 0.05$), in offspring exposed to
36 high LA ($P < 0.01$). Hepatic expression of lipogenic genes suggested an increase in lipogenesis
37 in male offspring exposed to a high-36% fat maternal diet and in female offspring exposed to
38 a low LA diet, via increases in the expression of *Fasn* and *Srebf1*. Sexually dimorphic
39 responses to altered maternal diet appeared to persist until two weeks-of-age. In conclusion,
40 whilst maternal total fat content predominantly affected offspring growth, fatty acid ratio and
41 total fat content had sexually dimorphic effects on offspring liver morphology-weight and
42 composition.

43 Introduction

44 Accumulating evidence suggests that the nutritional environment experienced by an individual
45 during fetal and early infant development has long-lasting impacts on their metabolic health ⁽¹⁾.
46 In the context of the global epidemic of obesity and nutritional excess, there has been
47 considerable interest in determining the effects of maternal overnutrition on the metabolic
48 health of the offspring. The majority of these studies have utilised animal models and have
49 consistently reported that maternal high-fat feeding during pregnancy has detrimental effects
50 on the metabolic health of both the mother and her offspring ^(2,3). As a result, excess maternal
51 fat consumption has been implicated as a key contributor to metabolic programming of long-
52 term health and disease risk.

53 There is increasing evidence, however, that the impact of a high-fat diet on the metabolic
54 health of the offspring depends not only on the amount of fat in the diet, but also on the fatty
55 acid composition ^(4,5). There has been particular interest in the role of two classes of
56 polyunsaturated fatty acids (PUFA), due to the substantive increase in the amounts of omega-
57 6 PUFA, predominately linoleic acid (LA), being consumed in the diets of many Western
58 countries over the past few decades ^(6,7). This increase in the intake of LA intakes has not
59 been accompanied by substantial changes in the consumption of omega-3 PUFA such as
60 alpha-linolenic acid (ALA) and has therefore resulted in increases in the ratio of omega-
61 6:omega-3 PUFA consumed in the diets of many Western countries ^(6,8).

62 The increasing dominance of omega-6 over omega-3 PUFA in modern Western diets has
63 considerable biological significance, since the omega-6 and omega-3 fatty acid families
64 utilise the same enzymes for production of longer chain bioactive derivatives such as
65 arachidonic acid (AA; omega-6), eicosapentaenoic acid (EPA; omega-3), docosapentaenoic
66 acid (DPA; omega-3) and docosahexaenoic acid (DHA; omega-3), and also compete for
67 incorporation into cell membranes. As a result, excess consumption of LA leads to a decrease
68 in the production and incorporation of omega-3 fatty acids through simple substrate
69 competition, and this effect is exacerbated when total dietary PUFA is high ^(9,10). The omega-
70 3 and omega-6 long-chain polyunsaturated fatty acids (LCPUFA) derivatives also have
71 opposing physiological actions, with those from the omega-3 family predominately
72 exhibiting anti-inflammatory properties (for example via the suppression of the pro-
73 inflammatory transcription factor nuclear factor kappa B and activation of the anti-
74 inflammatory transcription factor peroxisome proliferator activated receptor γ ⁽¹¹⁾) and those

75 from the omega-6 family exhibiting more pro-inflammatory and pro-adipogenic properties
76 ⁽¹²⁾. This has led to the hypothesis that the increasing ratio of omega-6 to omega-3 fatty acids
77 in modern Western diets may have negative effects on conditions characterised by low-grade
78 inflammation, including obesity and the metabolic syndrome, and may potentially be
79 contributing to an intergenerational cycle of obesity ⁽⁸⁾.

80 Data from observational studies in humans and animal models provide supporting evidence
81 that suggests high intakes of omega-6 PUFA during pregnancy could have negative effects on
82 metabolic health of the progeny ^(13,14,15). However, the results of these studies have not been
83 consistent. The results of pre-clinical studies are also limited by the use of diets with much
84 higher omega-6:omega-3 PUFA ratios and/or absolute PUFA contents than those encountered
85 in typical human diets. Furthermore, offspring often continue to have access to the same diet
86 as their mother so that any effects observed cannot be clearly attributed to dietary fatty acid
87 exposure during the gestation and lactation periods ^(16,17,18). The aim of this study, therefore,
88 was to investigate the effects of feeding a maternal dietary LA:ALA ratio similar to that of
89 the Western diet (9:1) ⁽⁶⁾, compared to a proposed 'ideal' ratio of 1:1.5 ^(19,20) on growth and
90 ~~fat deposition~~ lipogenic gene expression of ~~in~~ the offspring. Since total dietary PUFA intake
91 also influences PUFA metabolism ^(9,10), we also investigated the effect of feeding each dietary
92 fat ratio at either 18% fat w/w (in line with dietary recommendations ⁽²¹⁾) or at a higher fat
93 level of 36% fat w/w. A rat model was utilised to achieve the study objectives by allowing for
94 tight control of dietary manipulation as well as invasive end points.

95

96 **Materials and Methods**

97 *Animals*

98 All animal procedures were performed in accordance with the Animals (Scientific Procedures)
99 Act 1986 under Home Office licence and were approved by the Animal Ethics Committee of
100 the University of Nottingham, UK. Virgin female Wistar rats (n=30; 75-100g; Charles River,
101 UK) were housed on wood shavings in individually ventilated cages under a 12 hour light/12
102 hour dark cycle at a temperature of 20-22°C and had *ad libitum* access to food and water
103 throughout the experiment. Female rats were allowed to acclimatise to the unit for 1-2 weeks,
104 during which time they were fed standard laboratory chow (2018 Teklad Global 18% Protein
105 Rodent Diet, Harlan Laboratories, UK). After acclimatisation, a tail vein blood sample was
106 taken from each animal for the determination of fatty acid status. The rats were then randomly

107 assigned to one of 4 dietary groups (details provided below). Animals were maintained on their
108 allocated diet for a four week 'pre-feeding' period, after which they were mated. Conception
109 was confirmed by the presence of a semen plug and this was recorded as day 0 of pregnancy.
110 Animals were housed in individual cages and remained on their respective diets throughout
111 pregnancy and lactation.

112

113 Litters were standardised to 8 pups within 24 hours of birth (4 males and 4 females, where
114 possible). At 1 and 2 weeks of age, one randomly selected male and one randomly selected
115 female from each litter were culled via cervical dislocation and exsanguination for blood and
116 tissue collection. At 3 weeks of age, the remaining offspring were weaned and dams were then
117 euthanised by CO₂ asphyxiation and cervical dislocation for collection of maternal blood and
118 tissues. All dams were weighed and had feed intake measured daily throughout the experiment
119 and offspring bodyweight was measured weekly.

120

121 *Diets*

122 Diets were designed to provide either a high (9:1, high LA) or low (1:1.5, low LA) ratio of LA
123 ([cis/cis isomer](#)) to ALA, achieved by altering the amounts of flaxseed and sunflower oil
124 included in the fat component of the feed. The levels of saturated and monounsaturated fatty
125 acids were comparable in all diets, achieved by adjusting the amounts of coconut (saturated fat
126 source) and macadamia (monounsaturated fat source) oils in the diets. For each level of LA,
127 diets were developed to containing either 18% fat (w/w), in line with government
128 recommendations ⁽²¹⁾, or 36% fat (w/w) to highlight any additive effects were developed (38.6
129 vs 63.5% of dietary energy respectively). This resulted in four experimental diets (n=6-9 per
130 dietary group); high LA (18% fat), high LA (36% fat), low LA (18% fat) and low LA (36%
131 fat). The list of ingredients and final fatty acid composition of the four experimental diets have
132 been reported previously ⁽⁵⁾.

133

134 *Blood sample and tissue collection*

135 Blood samples were collected from dams prior to the start of the experiment and after the 4
136 week 'feed-in' period (tail vein sample) and at the end of lactation (via cardiac puncture
137 following CO₂ asphyxiation and cervical dislocation). Truncal blood samples were also
138 collected from one randomly selected male and one randomly selected female at 1 and 2 weeks
139 of age. In all cases, samples of whole blood (~30µl) from non-fasted animals were spotted onto
140 PUFAcoat™ dried blood spot (DBS) collection paper ⁽²²⁾, allowed to dry at room temperature

141 and stored at -20°C for subsequent fatty acid analysis. Maternal tissues were weighed and
142 samples of whole liver, retroperitoneal and gonadal adipose tissues collected. Offspring body
143 and organ weights were measured and whole liver samples were collected from one randomly
144 selected male and female pup at both time points. At 2 weeks of age, samples of gonadal and
145 retroperitoneal fat were also collected from one male and one female pup per litter. All tissue
146 samples were snap-frozen in liquid nitrogen and stored at -80°C until determination of gene
147 expression by quantitative reverse transcriptase PCR (qRT-PCR).

148

149 *Fatty acid methylation and analysis*

150 Fatty acid composition in maternal and fetal blood was determined as previously described ⁽²²⁾.
151 Briefly, whole DBS samples were directly transesterified with 2ml of 1% H₂SO₄ in methanol
152 and the fatty acid methyl esters (FAME) were extracted with heptane. Samples were separated
153 and analysed by a Hewlett-Packard 6890 gas chromatograph (GC) equipped with a capillary
154 column (30m x 0.25mm) coated with 70% cyanopropyl polysilphenylene-siloxane (BPX-70;
155 0.25µm film thickness) which was fitted with a flame ionization detector (FID). FAMES were
156 identified in unknown samples based on the comparison of retention times with an external
157 lipid standard (Standard 463, Nu-check prep Inc., MN, USA) using Agilent Chemstation
158 software (Agilent Technologies Australia Pty Ltd). Individual fatty acid content was calculated
159 based on peak area and response factors normalised to total fatty acid content and expressed as
160 a percentage of total fatty acids.

161

162 *Isolation of RNA and cDNA synthesis and quantitative reverse transcription real-time PCR* 163 *(qRT-PCR)*

164 RNA was isolated from crushed snap-frozen samples of ~25mg of liver using the Roche High
165 Pure Tissue kit (Roche Diagnostics Ltd., UK). Adipose RNA was extracted, after
166 homogenisation of ~100mg of tissue with MagNA lyser green beads and instrument (Roche
167 Diagnostics Ltd.), using the RNeasy Mini Kit (QIAGEN Ltd., UK). RNA concentration was
168 determined using a Nanodrop 2000 (Thermo Scientific) and RNA quality was evaluated by
169 agarose gel electrophoresis. cDNA was synthesised using a RevertAid™ reverse transcriptase
170 kit (Thermo Fisher Scientific, UK) with random hexamer primers.

171

172 Lipogenic pathway and adipokine target genes were chosen based on previous data from our
173 laboratory that indicated that these genes were sensitive to changes in the maternal diet⁽²³⁾ and
174 included; peroxisome proliferator-activated receptor gamma (*Pparg*), sterol regulatory

175 element-binding protein (variant 1c; *Srebf1*), fatty acid synthase (*Fasn*), lipoprotein lipase (*Lpl*)
176 and leptin (*Lep*), with β -actin (*Actb*) as the housekeeper. Primer efficiency ranged from 85%-
177 108% and sequences have previously been published elsewhere ⁽⁵⁾. Adipocyte and hepatic gene
178 expression was quantified using SYBR Green (Roche Diagnostics) in a Light-Cycler 480
179 (Roche Diagnostics). Samples were analysed against a standard curve of a serially diluted
180 cDNA pool to produce quantitative data and expression was normalised to the housekeeping
181 gene using LightCycler® 480 software (version 1.5.1) as previously described ⁽²⁴⁾. The
182 expression of the housekeeper gene was not different between treatment groups.

183

184 *Determination of liver DNA, protein and glycogen content*

185 For determination of DNA and protein content of liver samples, approximately 100mg of
186 frozen crushed sample was added to 1ml of 0.05M trisodium citrate buffer. Samples were
187 homogenised and centrifuged at 2500rpm for 10 minutes at 4°C. Supernatant was used for
188 further analyses. DNA concentration (ug/ml) was measured using a Hoechst fluorimetric
189 method and protein content (ug/well), modified for a 96 well plate format, was measured as
190 described by Lowry *et al.* ⁽²⁵⁾. Measurements were normalised to the exact amount of tissue
191 used for measurements. Liver glycogen was measured using the Colorimetric Glycogen
192 Assay Kit II (Abcam Ltd.) according to manufacturer's instructions.

193

194 *Statistical analysis*

195 Data are presented as mean \pm SEM. Data were analysed using the Statistical Package for Social
196 Sciences (Version 24, SPSS Inc.). The effect of maternal dietary fatty acid ratio and maternal
197 dietary fat content on maternal dependent variables was assessed using a two-way ANOVA,
198 with dietary LA:ALA ratio and dietary fat content as factors and dams were used as the unit of
199 analysis. Where longitudinal data were analysed, as with maternal feed, protein and energy
200 intakes, the impact of maternal dietary LA:ALA ratio and maternal dietary fat content was
201 analysed using a two-way repeated-measures ANOVA. Offspring data were analysed using a
202 two-way ANOVA, with maternal dietary LA:ALA ratio and fat content as factors; where there
203 was no overall effect of sex, male and female offspring data were combined. Where data were
204 not normally distributed, analyses were performed on log₁₀ transformed data. A value of
205 $P < 0.05$ was considered to be statistically significant.

206

207 **Results**

208 *Maternal dietary intakes*

209 There were no differences in feed intake of dams between treatment groups before or during
210 pregnancy. During lactation, dams receiving the 36% fat diets had a lower average daily feed
211 intake than those receiving the 18% fat diets, irrespective of dietary LA:ALA ratio ($P<0.001$;
212 Fig 1a). Energy intake was similar between groups throughout the experiment (Fig. 1b). Protein
213 intake prior to and during pregnancy was affected by both dietary LA:ALA ratio and fat content
214 ($P<0.05$; Fig. 1c), however, these effects were small and inconsistent. During lactation, protein
215 intake was affected by dietary fat content only ($P<0.001$; Fig. 1c), such that mothers receiving
216 ~~high-36%~~ fat diets (~~36% fat~~) consumed 24% less protein on average compared to those
217 consuming ~~lower-(18%)~~ fat diets, irrespective of dietary LA:ALA ratio. As expected, all dams
218 consumed more food, energy and protein during lactation than before and during pregnancy
219 regardless of dietary group ($P<0.001$).

220

221 *Maternal fatty acid profile*

222 There were no differences in the proportions of either saturated fatty acids (SFA),
223 monounsaturated fatty acids (MUFA), omega-6 (Fig. 2a) or omega-3 PUFA (Fig. 2b) in whole
224 blood samples collected from the dams prior to the commencement of dietary intervention.
225 After 4 weeks on their respective diets, the blood fatty acid profiles were significantly different
226 between treatment groups and largely reflected the composition of the experimental diets.
227 Thus, dams fed on high LA diets had higher proportions of LA (1.2 fold) and AA (1.4 fold)
228 compared to those consuming a low LA diet ($P<0.001$; Fig. 2c). Conversely, dams fed the low
229 LA diets had a 5.5 fold higher proportion of ALA and an 8.5 fold higher proportion of EPA
230 compared to those consuming a high LA diet ($P<0.001$; Fig. 2D). These changes were
231 independent of the total fat content of the diet. DPA and DHA levels after the 4 week pre-
232 feeding period were influenced by both dietary LA:ALA ratio and total fat content. Thus, the
233 relative proportions of DPA were higher in dams fed the low LA compared to high LA diets
234 ($P<0.001$), and marginally higher in dams consuming the 18% vs 36% fat diets ($P<0.05$). DHA
235 proportions were also higher in the low LA group ($P<0.001$) but, unlike DPA, were modestly
236 but significantly higher in dams consuming the 36% fat vs 18% fat diets ($P<0.05$; Fig. 2D).
237 Total blood MUFA proportions were higher (1.3-fold) in dams consuming the low LA diet,
238 irrespective of dietary fat content ($P<0.001$; Fig. 2C).

239

240 The blood fatty acid profile of the dams at the end of lactation, after a further 6 weeks on their
241 respective experimental diets, were similar to those observed after the first 4 weeks of dietary
242 intervention. A notable difference, however, was that at this time point, relative proportions of
243 DHA, as a percentage of total lipids, were not different between dietary groups (Fig. 2F). LA
244 (1.5-fold), AA (1.8-fold) and total omega-6 (1.5-fold) were all higher in dams consuming a
245 high LA diet irrespective of dietary fat content ($P < 0.001$; Fig. 2E). Conversely, total omega-3
246 levels were 3-fold higher in dams consuming a low LA diet, irrespective of dietary fat content
247 ($P < 0.001$). The proportions of ALA were also higher in the groups consuming the low LA diets
248 and in rats consuming the 36% vs 18% fat diets in the low LA group only ($P < 0.05$; Fig 2F).
249 DPA proportions were higher in the groups consuming the low LA diets, however, unlike ALA,
250 DPA proportions were lower, rather than higher, in dams consuming the 36% fat diets in the
251 low LA group only ($P < 0.001$; Fig. 2F). EPA proportions were higher in groups consuming a
252 low LA diet compared to those consuming a high LA diet ($P < 0.001$; Fig. 2F). EPA proportions
253 were also affected by total dietary fat content, and were lower in dams consuming a ~~high-36%~~
254 ~~fat (36% fat)~~ diet compared to an ~~lower-(18% fat)~~ diet ($P < 0.001$; Fig. 2F). Maternal blood total
255 MUFA levels at the end of lactation were 1.4-fold higher in the dams consuming a low LA diet
256 irrespective of dietary fat content ($P < 0.001$; Fig. 2E).

257

258 *Maternal weight, body composition and gene expression*

259 There were no significant differences in dam bodyweight between dietary groups prior to the
260 commencement of the dietary intervention or at any time during the experiment (data not
261 shown). Dams consuming the 36% fat diets had heavier lungs relative to bodyweight at the end
262 of lactation compared to those consuming the 18% fat diets, independent of the LA:ALA ratio
263 ($P < 0.05$). There were no differences in the relative weight of the heart, liver, brain, kidney,
264 gonadal or retroperitoneal fat pads between experimental groups (Table 1).

265

266 Analysis of mRNA expression of lipogenic genes indicated that hepatic (3-fold) and gonadal
267 fat (7-fold) expression of *Fasn* was higher in dams consuming an 18% fat diet, compared to
268 those on a 36% fat diet, irrespective of dietary fatty acid ratio ($P < 0.01$). The mRNA expression
269 of *Lpl*, *Pparg* and *Srebf1* was not, however, affected by either dietary fat content or ratio in
270 either hepatic or gonadal fat tissues (Table 1). Expression of leptin mRNA in gonadal adipose
271 tissue was not significantly different between treatment groups.

272

273 *Birth outcomes and offspring bodyweights*

274 There were no differences between dietary groups in terms of litter size or sex ratio of pups
275 (Table 2). Birth weight was lower in offspring of dams fed a 36% fat vs 18% fat diets,
276 independent of the dietary LA:ALA ratio (Table 2). The lower body weight in offspring of
277 dams fed the 36% fat diet persisted during the suckling period such that offspring of dams fed
278 the 36% fat diets remained lighter than offspring of dams fed on 18% fat diets at both 1 and 2
279 weeks of age; again this was independent of dietary LA:ALA ratio ($P < 0.001$; Table 3).

280

281 *Offspring fatty acid profile*

282 At 1 week of age, proportions of AA (2.1 fold) were lower in the offspring of the low LA
283 compared to high LA dams ($P < 0.001$), and in offspring of dams consuming the 36% fat vs 18%
284 fat diets (1.4 fold; $P < 0.001$; Fig. 3A). Blood ALA proportions were 5.9 fold higher in offspring
285 of dams in the low LA groups compared to high LA groups ($P < 0.001$; Fig. 3B). Offspring EPA
286 and DPA proportions were also higher in the low LA group compared to the high LA group.
287 Blood EPA was also influenced by total dietary fat content, but only in offspring of dams fed
288 the low LA diet, in which EPA levels were lower in offspring of dams fed the 36% fat diets
289 compared to the 18% fat diets (EPA, $P < 0.001$; DPA, $P < 0.01$; Fig. 3B). DHA proportions were
290 not different between groups at 1 week of age (Fig. 3B). MUFA proportions were higher (1.2-
291 fold) in offspring of dams in the low LA groups ($P < 0.001$), consistent with the pattern in
292 maternal blood. However, unlike maternal MUFA, offspring MUFA levels were also affected
293 by maternal dietary fat content and were 1.2-fold higher in offspring of dams fed the 36% fat
294 vs 18% fat diets ($P < 0.001$; Fig. 3A). At 1 week of age offspring of dams in the 36% fat diet
295 groups also had lower blood proportions of SFA, irrespective of LA:ALA ratio of the maternal
296 diet ($P < 0.01$; Fig. 3A).

297

298 The fatty acid profiles of the offspring at 2 weeks of age were similar to those observed at 1
299 week. Thus, blood AA (1.9 fold) and total omega-6 (1.6 fold) proportions were lower (Fig. 3C)
300 and ALA (6.3 fold), EPA (4.7 fold), DPA (2.4 fold) and total omega-3 PUFA (3-fold)
301 proportions (Fig. 3D) were higher in offspring of dams in the low LA group compared to high
302 LA groups, irrespective of maternal dietary fat content ($P < 0.001$). Proportions of LA were
303 higher in offspring of dams fed the 36% fat diets compared to those fed 18% fat diets in the
304 high LA group only ($P < 0.05$; Fig 3C), while EPA and DPA proportions were lower in the 36%
305 compared to the 18% fat diet groups, independent of the dietary LA:ALA ratio ($P < 0.001$; Fig.
306 3D). Unlike findings at 1 week of age, the DHA levels in 2 week old offspring of dams
307 consuming a 36% fat diet were lower ($P < 0.05$) when compared to 18% fat groups, irrespective

308 of maternal dietary fatty acid ratio. As at 1 week, SFA proportions were lower (1.2-fold) in
309 offspring of dams fed a ~~high-36%~~ fat (~~36%~~) diet, independent of the LA:ALA ratio ($P<0.001$).
310 MUFA proportions were 1.2 fold higher in offspring of dams fed the low LA diets, and 1.2
311 fold higher in offspring of dams who consumed a 36% fat vs 18% diet ($P<0.001$; Fig. 3C).

312

313 *Offspring organ weight and liver composition*

314 At 1 week of age, heart weight relative to bodyweight was higher in female offspring of dams
315 receiving a ~~high-(36%)~~ fat diet compared to the 18% fat diet, independent of the dietary
316 LA:ALA ratio ($P<0.05$). There were no differences in the relative weight of lung or kidney at
317 1 week of age and no differences in the relative weight of the heart, lung, liver, gonadal or
318 retroperitoneal fat pads in the offspring at 2 weeks of age between treatment groups in either
319 male or female offspring (Table 3).

320

321 Liver weight at 1 week appeared to be influenced by the LA:ALA ratio of the diet to a greater
322 extent than total fat level, at least in males. Thus, male offspring of dams consuming the high
323 LA diets had increased liver weights compared to offspring of dams receiving a low LA diet
324 ($P<0.01$), irrespective of total dietary fat content. The glycogen content of the livers was also
325 higher in male offspring of dams consuming the high LA diets at 1 week of age ($P<0.05$). No
326 effect of maternal diet on offspring liver protein or DNA concentration was observed (Table
327 4). These differences were not present in females at 1 week of age and no differences in
328 glycogen content were observed at two weeks of age in male offspring. DNA concentration in
329 females at two weeks of age was marginally increased (1.1-fold) in offspring exposed to a ~~high-~~
330 ~~36%~~ fat diet, irrespective of maternal dietary fatty acid ratio ($P<0.05$).

331

332 *Hepatic gene expression*

333 At 1 week of age, hepatic *Fasn* expression was influenced by maternal dietary intervention in
334 a sex specific manner. Thus, in males, *Fasn* expression was higher in offspring of dams
335 consuming a ~~high-36%~~ fat (~~36%~~) diet irrespective of maternal LA:ALA ratio ($P<0.05$). In
336 female offspring, however, *Fasn* expression was higher in offspring of dams consuming a low
337 LA diet, independent of dietary fat content ($P<0.05$). Hepatic *Lpl* mRNA expression in male
338 offspring at 1 week of age was also influenced by maternal dietary fat content, with higher
339 expression in offspring of dams consuming a 36% fat diet vs a ~~low-~~18% fat diet ($P<0.05$). In
340 female offspring, hepatic *Srebf* expression, similar to that of *Fasn*, was higher in offspring of
341 dams consuming a low LA diet at 1 and 2 weeks of age ($P<0.01$). Female hepatic expression

342 of *Pparg* was lower in offspring of dams consuming a low LA diet at 2 weeks of age ($P < 0.05$).
343 There were no differences in the expression of *Fasn* or *Lpl* in female offspring, or expression
344 of any hepatic genes in male offspring at this time point (Table 3).

345

346 **Discussion**

347 This study has demonstrated that altering the fat content and/or LA:ALA ratio of the maternal
348 diet during pregnancy and lactation resulted in significant alteration in the circulating fatty acid
349 profile of dams in the absence of any significant effects on maternal bodyweight or body
350 composition. Exposure to a **high-36%** fat diet during gestation and lactation was, however,
351 associated with lower offspring bodyweight from birth, which persisted to 2 weeks of age. This
352 suggests that increased dietary fat intake during pregnancy and lactation can compromise
353 growth of the progeny, irrespective of the type of fat consumed. In addition, alterations in the
354 fat content and/or composition of the maternal diet had transient effects on offspring body
355 composition and hepatic gene expression, effects which were also sex-specific.

356

357 Maternal fatty acid profiles after 4 weeks on the experimental diets largely reflected dietary
358 composition, confirming that the dietary intervention had the desired effect on maternal
359 circulating fatty acid composition. These changes persisted after a further 6 weeks of exposure
360 to the diets and, as expected, the dietary LA:ALA ratio had a greater impact on the maternal
361 blood omega-6 and omega-3 status than total dietary fat content. Consistent with previous
362 studies ^(5,9,26,27), decreasing the dietary LA:ALA ratio resulted in substantial increases in
363 relative maternal ALA and EPA levels but only a very modest increase in DHA proportions
364 after a 4-week exposure, and no difference compared to the higher LA:ALA ratio after 10
365 weeks. Interestingly, and independent of dietary LA:ALA ratio, dams appeared to be more
366 efficient at converting DPA to DHA when total dietary fat load was higher. One possibility **is**
367 **could be** that this is simply a result of the higher amount of substrate (i.e. ALA) available for
368 conversion to the longer chain derivatives such as DPA and DHA in diets containing higher
369 total fat levels. This effect did not, however, persist after a further 6 weeks of dietary exposure,
370 at which point EPA and DPA were lower in dams consuming a low LA 36% fat diet compared
371 to a low LA 18% fat diet. This may be a result of saturation of the PUFA metabolic pathway
372 when total fat, and therefore PUFA, levels were higher ^(10,28). This apparent decrease in capacity
373 to convert ALA through to EPA and DHA during consumption of a **high-36%** fat diet coincides
374 with the decreased protein intake observed in these groups. It is possible that the lower
375 consumption of protein in rats fed on the 36% fat diets may have contributed to reduced

376 conversion of ALA, since previous studies have shown reduced desaturase, particularly $\Delta 6$ -
377 desaturase, expression in the mammary gland ⁽²⁹⁾ and liver ⁽³⁰⁾ of rats exposed to a low protein
378 diet. Maternal whole blood MUFA proportions appeared to be influenced by dietary LA:ALA
379 ratio, however, this is most likely a result of the slightly higher MUFA content of the low LA
380 diets.

381

382 Offspring fatty acid profiles at 1 and 2 weeks of age largely reflected maternal profiles with
383 maternal dietary LA:ALA ratio exhibiting the strongest effect on offspring circulating fatty
384 acid proportions. However, the total fat content of the maternal diet appeared to have a greater
385 influence on the blood fatty acid composition of the offspring ~~thanas~~ opposed to that observed
386 in the dams. Of particular interest was the finding that the proportion of both EPA and DPA in
387 offspring at 1 week of age were higher in the low LA (18% fat) vs the low LA (36% fat) group,
388 and that this effect persisted at 2 weeks of age despite ALA levels being increased in the low
389 LA (36% fat) group at this time point. DHA was not different between groups at 1 week of age
390 but was lower in offspring exposed to a high-36% fat diet at 2 weeks of age. As with the
391 maternal fatty acid profiles, this again may be a result of saturation of the PUFA metabolic
392 pathway at higher total PUFA intakes, and is in line with findings from numerous studies, both
393 human and animal, that indicate that simply increasing the quantity of substrate, i.e. ALA, is
394 not an effective strategy for increasing concentrations of its long-chain derivatives, in particular
395 DHA ^(26,27,31,32).

396

397 The total dietary fat content of the maternal diet also had an influence on the proportion of SFA
398 in the offspring, such that offspring of dams consuming high-36% fat diets exhibited lower
399 SFA proportions than offspring of dams consuming the lower18% fat diets. Unlike the fetus,
400 where fatty acid composition is largely related to maternal dietary intake, during suckling,
401 offspring fatty acid composition is largely determined by the composition of the milk, which
402 may not fully reflect maternal fatty acid intakes. In a study by Mohammad *et al.* ⁽³³⁾, for
403 example, women consuming diets with a higher total fat content (55%en vs. 25%en) exhibited
404 reduced SFA concentrations (C6:0-C14:0) in breast milk but not in maternal plasma. While
405 milk composition was not assessed in the current study, this raises the possibility that SFA
406 content of the milk may have been lower in those dams consuming the 36% fat diets, which
407 could in turn explain the lower SFA status of the offspring. Alternatively, it may be that
408 increasing the fat content of the diets resulted in an increased conversion of SFA to MUFA,
409 since high-fat feeding has been associated with increased expression of the enzyme responsible

410 for conversion of SFA to MUFA, stearoyl-CoA desaturase 1 (SCD-1) ⁽³⁴⁾ and could therefore
411 be the reason for the observed effect of fat content on offspring MUFA levels in this study. It
412 is important to note, however, that circulating fatty acid profiles are a product of both dietary
413 fatty acid intake as well as tissue fatty acid production and release. Whilst the collection of
414 blood samples from animals in the fed state suggests that the dietary fraction of fatty acids
415 would provide a greater contribution to the fatty acid profile of both dams and offspring, the
416 influence of hepatic synthesis of fatty acids should not be overlooked as a contributor to the
417 observed differences.

418

419 Despite significant shifts in maternal fatty acid profiles and increased fat content of the 36%
420 fat diets, we saw no differences in maternal bodyweight or fat deposition. This is consistent
421 with our previous study ⁽⁵⁾ and is likely a result of the reduced feed intakes of the dams to
422 compensate for the increased energy density of the higher fat diets, a phenomenon consistently
423 seen with dietary intervention trials using rodents ⁽³⁵⁾. Despite the lack of an effect on maternal
424 weight gain and fat deposition, bodyweight was reduced in offspring of dams receiving a high-
425 36% fat (36%-fat) diet, irrespective of maternal dietary LA:ALA ratio. This phenotype was
426 consistent across sexes and persisted from birth to 2 weeks of age. Variable results have been
427 reported in this regard with some studies reporting no effects ^(36,37,38) or increased weight ⁽³⁹⁾.
428 This finding was, however, consistent with many other studies that reported decreased fetal
429 ^(40,41), birth ⁽⁴²⁾ and weaning weight ⁽⁴³⁾ in offspring of dams exposed to a high-36% fat diet
430 during gestation and lactation periods. The differential effects of different high-36% fat diets
431 on offspring growth is likely due to differences in composition of the diet as well as periods of
432 exposure between studies ⁽³⁾. In those studies that have reported lower offspring weights in
433 offspring fed a high-fat diet, lower protein intakes in dams consuming a high-fat diet have been
434 cited as a likely contributing factor. Further to this, protein restricted diets have been associated
435 with impaired mammary gland development ^(29,44) leading to impaired milk synthesis ⁽⁴⁴⁾, and
436 this may also have contributed to reduced offspring growth observed during the suckling
437 period. It is important to note however, that the reduction in protein intake in high-fat dams
438 consuming a 36% fat diet in the current study were more modest (10-25%) than those typically
439 used in low-protein diet studies (~50% reduction) ^(45,46,47,48).

440

441 The lower *Fasn* expression in the liver and adipose tissue of dams exposed to a high-36% fat
442 diet is consistent with the established role of this enzyme in suppressing lipogenesis in times
443 of energy excess ⁽⁴⁹⁾. Surprisingly, this change did not appear to be mediated through changes

444 in maternal *Srebf1* mRNA expression, a known regulator of *Fasn* expression⁽⁵⁰⁾. It is important
445 to note that since only mRNA expression was measured, we cannot comment on any
446 differences in protein expression or activity of this transcription factor although mRNA and
447 protein levels have been shown to be closely correlated⁽²³⁾. [Following this up at the protein](#)
448 [level is a major priority for future study](#). In the offspring, however, hepatic *Fasn* expression
449 was not downregulated by exposure to a maternal ~~high-36%~~ fat diet but was actually higher in
450 male offspring of dams consuming the 36% fat compared to the 18% fat diets at 1 week of age
451 and was accompanied by an increase in *Lpl* expression. In female offspring, however, hepatic
452 *Fasn* and *Sbrefl* expression at 1 week were influenced by maternal dietary fatty acid ratio,
453 rather than total fat content, with both genes upregulated in offspring of dams fed the low LA
454 diets. In both cases, the upregulation of *Sbrefl*, *Fasn* and *Lpl* genes would be expected to be
455 associated with an upregulation of both lipogenesis and fatty acid uptake. It is worth
456 mentioning that differences in hepatic expression of lipogenic genes in male offspring were
457 consistently associated with maternal dietary fat content whereas differences in female hepatic
458 expression were consistently associated with maternal dietary fatty acid ratio. This suggests
459 that female offspring are more sensitive to changes in the types of maternal dietary fat whereas
460 male offspring are more sensitive to gross maternal fat consumption. Sex specific effects
461 associated with the programming of disease hypothesis have been frequently reported⁽⁵¹⁾. The
462 mechanism by which sex influences these effects, however, remains to be elucidated within a
463 larger perspective, as well as within the context of this study.

464
465 We found no evidence that these alterations in hepatic gene expression translated to increases
466 in liver weight, however whether there was any effect on hepatic fat content remains to be
467 determined. In both male and female offspring, relative liver weight was increased in offspring
468 of dams fed the high LA diet. In an aim to further elucidate the source of this increased weight,
469 we measured liver DNA, protein and glycogen composition. Similar to liver weight, glycogen
470 levels were increased in offspring of dams fed the high LA diets. This increase in glycogen,
471 however, was not sufficient enough to completely account for the differences observed in liver
472 weight but may be a contributing factor. Consideration of DNA and protein content of the
473 tissue did not indicate significant changes to cell size or number. More detailed analysis is
474 required to further elucidate the mechanism by which high maternal dietary omega-6 may
475 impact upon offspring liver ~~morphology and~~ physiology.

476

477 The majority of the hepatic mRNA expression differences, as well as gross differences in liver
478 weight and composition, appeared to be transient and were no longer present at 2 weeks of age.
479 A notable exception was the lower expression of *Srebf1* mRNA and higher expression of *Pparg*
480 in females of dams exposed to a high LA diet compared to the low LA diet, with a similar trend
481 observed in males. Although found in relatively low concentrations in the liver, activation of
482 *Pparg* has been shown to increase hepatic lipid storage and is elevated in models of hepatic
483 steatosis ⁽⁵²⁾. As such, decreased *Pparg* expression can alleviate some of the symptoms of
484 hepatic steatosis leading to a reduced liver weight in conjunction with a reduction in hepatic
485 triglyceride content ⁽⁵³⁾. Thus, our finding that female offspring of dams exposed to a high LA
486 diet tended towards to have an increased liver weight at one week of age followed by increased
487 hepatic *Pparg* expression at two weeks of age may suggest that the increase in *Pparg*
488 expression is a potential response to the increased liver growth observed a week earlier.
489 Alternatively, parallels may be drawn to the effect of low protein diets where fluctuations
490 between an increased and decreased lipogenic capacity, chiefly mediated by altered *Srebf1*
491 expression, occur in early life only to settle into a pattern of upregulated lipogenesis at a later
492 life stage ⁽²³⁾. Further studies would be needed to directly evaluate this hypothesis.

493

494 In conclusion, we have demonstrated that exposure to a high-36% fat diet during gestation and
495 lactation is associated with persistent growth restriction in both male and female offspring
496 irrespective of maternal dietary fatty acid composition. Growth restriction has been associated
497 with a plethora of metabolic disturbances later in life ^(54,55,56) and transient alterations in gene
498 expression have been suggested as a mechanism for programming changes in metabolic
499 processes within tissues as well as the morphology of the tissues themselves ⁽¹⁾. In this study,
500 offspring are still exposed to the experimental diets via the dams milk, and further studies in
501 offspring at older ages are required to assess whether the changes in growth, hepatic gene
502 expression and liver weights in the current study are associated with phenotypic changes that
503 persist once offspring are no longer exposed directly to the altered diet composition. In
504 addition, analysis of lipogenic pathway and adipokines targets at the protein level, as well as
505 whole transcriptome analysis, may yield useful information about their regulation and the
506 extent to which these experimental diets programme other metabolic and regulatory pathways
507 in the liver. Further to this Finally, the longevity of these perturbations into later life, especially
508 when presented with secondary metabolic challenges such as aging, prolonged high-fat feeding
509 or in the case of female offspring, pregnancy, remains to be elucidated.

510 **Acknowledgements**

511 The authors gratefully acknowledge the staff at the Bio-Support Unit (University of
512 Nottingham) for help and advice with animal procedures and Zoe Daniel for assistance with
513 molecular analyses.

514

515 **Financial Support**

516 BSM is supported by a Career Development Fellowship from the National Health and Medical
517 Research Council of Australia (APP1083009)

518

519 **Conflicts of Interest**

520 None

521

522 **Author Contributions**

523 SCL-E, BSM and MJE participated in study design. SAVD carried out the study (assisted by
524 GG), data analysis and preparation of the manuscript which was revised and approved by SCL-
525 E, BSM, MJE and GG.

526 **References**

- 527 1. Langley-Evans SC (2015) Nutrition in early life and the programming of adult disease: a
528 review. *J Hum Nutr Diet* **28 Suppl 1**, 1-14.
- 529 2. Ribaroff GA, Wastnedge E, Drake AJ *et al.* (2017) Animal models of maternal high fat
530 diet exposure and effects on metabolism in offspring: a meta-regression analysis. *Obes Rev*
531 **18**, 673-686.
- 532 3. Ainge H, Thompson C, Ozanne SE *et al.* (2011) A systematic review on animal models of
533 maternal high fat feeding and offspring glycaemic control. *Int J Obes (Lond)* **35**, 325-335.
- 534 4. Muhlhausler BS, Ailhaud GP (2013) Omega-6 polyunsaturated fatty acids and the early
535 origins of obesity. *Curr Opin Endocrinol Diabetes Obes* **20**, 56-61.
- 536 5. Draycott SAV, Liu G, Daniel ZC *et al.* (2019) Maternal dietary ratio of linoleic acid to
537 alpha-linolenic acid during pregnancy has sex-specific effects on placental and fetal weights
538 in the rat. *Nutrition & Metabolism* **16**, 1.
- 539 6. Blasbalg TL, Hibbeln JR, Ramsden CE *et al.* (2011) Changes in consumption of omega-3
540 and omega-6 fatty acids in the United States during the 20th century. *The American Journal*
541 *of Clinical Nutrition* **93**, 950-962.
- 542 7. Sioen I, van Lieshout L, Eilander A *et al.* (2017) Systematic Review on N-3 and N-6
543 Polyunsaturated Fatty Acid Intake in European Countries in Light of the Current
544 Recommendations - Focus on Specific Population Groups. *Ann Nutr Metab* **70**, 39-50.
- 545 8. Ailhaud G, Massiera F, Weill P *et al.* (2006) Temporal changes in dietary fats: role of n-6
546 polyunsaturated fatty acids in excessive adipose tissue development and relationship to
547 obesity. *Prog Lipid Res* **45**, 203-236.
- 548 9. Tu WC, Cook-Johnson RJ, James MJ *et al.* (2010) Omega-3 long chain fatty acid synthesis
549 is regulated more by substrate levels than gene expression. *Prostaglandins Leukot Essent*
550 *Fatty Acids* **83**, 61-68.
- 551 10. Gibson RA, Neumann MA, Lien EL *et al.* (2013) Docosaehaenoic acid synthesis from
552 alpha-linolenic acid is inhibited by diets high in polyunsaturated fatty acids. *Prostaglandins*
553 *Leukot Essent Fatty Acids* **88**, 139-146.
- 554 11. Calder PC (2015) Marine omega-3 fatty acids and inflammatory processes: Effects,
555 mechanisms and clinical relevance. *Biochimica et Biophysica Acta (BBA) - Molecular and*
556 *Cell Biology of Lipids* **1851**, 469-484.
- 557 12. Massiera F, Saint-Marc P, Seydoux J *et al.* (2003) Arachidonic acid and prostacyclin
558 signaling promote adipose tissue development: a human health concern? *J Lipid Res* **44**, 271-
559 279.
- 560 13. Massiera F, Barbry P, Guesnet P *et al.* (2010) A Western-like fat diet is sufficient to
561 induce a gradual enhancement in fat mass over generations. *J Lipid Res* **51**, 2352-2361.
- 562 14. Korotkova M, Gabrielsson B, Lonn M *et al.* (2002) Leptin levels in rat offspring are
563 modified by the ratio of linoleic to alpha-linolenic acid in the maternal diet. *J Lipid Res* **43**,
564 1743-1749.
- 565 15. Much D, Brunner S, Vollhardt C *et al.* (2013) Effect of dietary intervention to reduce the
566 n-6/n-3 fatty acid ratio on maternal and fetal fatty acid profile and its relation to offspring
567 growth and body composition at 1 year of age. *Eur J Clin Nutr* **67**, 282-288.
- 568 16. Muhlhausler BS, Miljkovic D, Fong L *et al.* (2011) Maternal Omega-3 Supplementation
569 Increases Fat Mass in Male and Female Rat Offspring. *Frontiers in Genetics* **2**, 48.
- 570 17. Ibrahim A, Basak S, Ehtesham NZ (2009) Impact of maternal dietary fatty acid
571 composition on glucose and lipid metabolism in male rat offspring aged 105 d. *British*
572 *Journal of Nutrition* **102**, 233-241.
- 573 18. Muhlhausler BS, Gibson RA, Makrides M (2011) The effect of maternal omega-3 long-
574 chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation during pregnancy and/or

- 575 lactation on body fat mass in the offspring: a systematic review of animal studies.
576 *Prostaglandins Leukot Essent Fatty Acids* **85**, 83-88.
- 577 19. Gibson RA, Muhlhausler B, Makrides M (2011) Conversion of linoleic acid and alpha-
578 linolenic acid to long-chain polyunsaturated fatty acids (LCPUFAs), with a focus on
579 pregnancy, lactation and the first 2 years of life. *Matern Child Nutr* **7 Suppl 2**, 17-26.
- 580 20. Lands WEM (2000) Commentary on the Workshop Statement. *Prostaglandins,*
581 *Leukotrienes and Essential Fatty Acids (PLEFA)* **63**, 125-126.
- 582 21. SACN (2018) Draft Report: Saturated fats and health.
583 <https://www.gov.uk/government/consultations/saturated-fats-and-health-draft-sacn-report>
584 (accessed 03/12/2018 2018)
- 585 22. Liu G, Muhlhausler BS, Gibson RA (2014) A method for long term stabilisation of long
586 chain polyunsaturated fatty acids in dried blood spots and its clinical application.
587 *Prostaglandins Leukot Essent Fatty Acids* **91**, 251-260.
- 588 23. Erhuma A, Salter AM, Sculley DV *et al.* (2007) Prenatal exposure to a low-protein diet
589 programs disordered regulation of lipid metabolism in the aging rat. *Am J Physiol Endocrinol*
590 *Metab* **292**, E1702-1714.
- 591 24. Rhinn H, Scherman D, Escriou V (2008) One-step quantification of single-stranded DNA
592 in the presence of RNA using Oligreen in a real-time polymerase chain reaction
593 thermocycler. *Anal Biochem* **372**, 116-118.
- 594 25. Lowry OH, Rosebrough NJ, Farr AL *et al.* (1951) Protein measurement with the Folin
595 phenol reagent. *The Journal of biological chemistry* **193**, 265-275.
- 596 26. Blank C, Neumann MA, Makrides M *et al.* (2002) Optimizing DHA levels in piglets by
597 lowering the linoleic acid to alpha-linolenic acid ratio. *J Lipid Res* **43**, 1537-1543.
- 598 27. Brenna JT, Salem N, Sinclair AJ *et al.* (2009) α -Linolenic acid supplementation and
599 conversion to n-3 long-chain polyunsaturated fatty acids in humans. *Prostaglandins,*
600 *Leukotrienes and Essential Fatty Acids* **80**, 85-91.
- 601 28. Tu WC, Muhlhausler BS, Yelland LN *et al.* (2013) Correlations between blood and tissue
602 omega-3 LCPUFA status following dietary ALA intervention in rats. *Prostaglandins Leukot*
603 *Essent Fatty Acids* **88**, 53-60.
- 604 29. Bautista CJ, Rodriguez-Gonzalez GL, Torres N *et al.* (2013) Protein restriction in the rat
605 negatively impacts long-chain polyunsaturated fatty acid composition and mammary gland
606 development at the end of gestation. *Archives of medical research* **44**, 429-436.
- 607 30. Mercuri O, de Tomas ME, Itarte H (1979) Prenatal protein depletion and Delta9, Delta6
608 and Delta5 desaturases in the rat. *Lipids* **14**, 822-825.
- 609 31. Mantzioris E, James MJ, Gibson RA *et al.* (1994) Dietary substitution with an alpha-
610 linolenic acid-rich vegetable oil increases eicosapentaenoic acid concentrations in tissues. *Am*
611 *J Clin Nutr* **59**, 1304-1309.
- 612 32. Chan JK, McDonald BE, Gerrard JM *et al.* (1993) Effect of dietary alpha-linolenic acid
613 and its ratio to linoleic acid on platelet and plasma fatty acids and thrombogenesis. *Lipids* **28**,
614 811-817.
- 615 33. Mohammad MA, Sunehag AL, Haymond MW (2014) De novo synthesis of milk
616 triglycerides in humans. *American journal of physiology Endocrinology and metabolism* **306**,
617 E838-E847.
- 618 34. Hu CC, Qing K, Chen Y (2004) Diet-induced changes in stearyl-CoA desaturase 1
619 expression in obesity-prone and -resistant mice. *Obesity research* **12**, 1264-1270.
- 620 35. Keesey RE, Hirvonen MD (1997) Body weight set-points: determination and adjustment.
621 *J Nutr* **127**, 1875S-1883S.
- 622 36. Khan IY, Taylor PD, Dekou V *et al.* (2002) Gender-Linked Hypertension in Offspring of
623 Lard-Fed Pregnant Rats. *Hypertension* **41**, 168-175.

- 624 37. Khan IY, Dekou V, Douglas G *et al.* (2005) A high-fat diet during rat pregnancy or
625 suckling induces cardiovascular dysfunction in adult offspring. *Am J Physiol Regul Integr*
626 *Comp Physiol* **288**, R127-133.
- 627 38. Dyrskog SE, Gregersen S, Hermansen K (2005) High-fat feeding during gestation and
628 nursing period have differential effects on the insulin secretory capacity in offspring from
629 normal Wistar rats. *Rev Diabet Stud* **2**, 136-145.
- 630 39. Samuelsson AM, Matthews PA, Argenton M *et al.* (2008) Diet-induced obesity in female
631 mice leads to offspring hyperphagia, adiposity, hypertension, and insulin resistance: a novel
632 murine model of developmental programming. *Hypertension* **51**, 383-392.
- 633 40. Taylor PD, Khan IY, Lakasing L *et al.* (2003) Uterine artery function in pregnant rats fed
634 a diet supplemented with animal lard. *Exp Physiol* **88**, 389-398.
- 635 41. Mark PJ, Sisala C, Connor K *et al.* (2011) A maternal high-fat diet in rat pregnancy
636 reduces growth of the fetus and the placental junctional zone, but not placental labyrinth zone
637 growth. *Journal of Developmental Origins of Health and Disease* **2**, 63-70.
- 638 42. Howie GJ, Sloboda DM, Kamal T *et al.* (2009) Maternal nutritional history predicts
639 obesity in adult offspring independent of postnatal diet. *J Physiol* **587**, 905-915.
- 640 43. Cerf ME, Muller CJ, Du Toit DF *et al.* (2006) Hyperglycaemia and reduced glucokinase
641 expression in weanling offspring from dams maintained on a high-fat diet. *Br J Nutr* **95**, 391-
642 396.
- 643 44. Moretto VL, Ballen MO, Goncalves TS *et al.* (2011) Low-Protein Diet during Lactation
644 and Maternal Metabolism in Rats. *ISRN obstetrics and gynecology* **2011**, 876502.
- 645 45. Langlely SC, Jackson AA (1994) Increased systolic blood pressure in adult rats induced
646 by fetal exposure to maternal low protein diets. *Clinical science (London, England : 1979)*
647 **86**, 217-222; discussion 121.
- 648 46. Langlely-Evans SC, Nwagwu M (1998) Impaired growth and increased glucocorticoid-
649 sensitive enzyme activities in tissues of rat fetuses exposed to maternal low protein diets. *Life*
650 *Sciences* **63**, 605-615.
- 651 47. Ozanne SE, Martensz ND, Petry CJ *et al.* (1998) Maternal low protein diet in rats
652 programmes fatty acid desaturase activities in the offspring. *Diabetologia* **41**, 1337-1342.
- 653 48. Malandro MS, Beveridge MJ, Kilberg MS *et al.* (1996) Effect of low-protein diet-induced
654 intrauterine growth retardation on rat placental amino acid transport. *The American journal of*
655 *physiology* **271**, C295-303.
- 656 49. Geelen SN, Blazquez C, Geelen MJ *et al.* (2001) High fat intake lowers hepatic fatty acid
657 synthesis and raises fatty acid oxidation in aerobic muscle in Shetland ponies. *Br J Nutr* **86**,
658 31-36.
- 659 50. Griffin MJ, Sul HS (2004) Insulin regulation of fatty acid synthase gene transcription:
660 roles of USF and SREBP-1c. *IUBMB Life* **56**, 595-600.
- 661 51. Gabory A, Roseboom TJ, Moore T *et al.* (2013) Placental contribution to the origins of
662 sexual dimorphism in health and diseases: sex chromosomes and epigenetics. *Biology of Sex*
663 *Differences* **4**, 5.
- 664 52. Inoue M, Ohtake T, Motomura W *et al.* (2005) Increased expression of PPAR γ in high fat
665 diet-induced liver steatosis in mice. *Biochemical and Biophysical Research Communications*
666 **336**, 215-222.
- 667 53. Gavrilova O, Haluzik M, Matsusue K *et al.* (2003) Liver peroxisome proliferator-
668 activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and
669 regulation of body fat mass. *The Journal of biological chemistry* **278**, 34268-34276.
- 670 54. Barker DJ (1995) Fetal origins of coronary heart disease. *BMJ* **311**, 171-174.
- 671 55. Phillips DI, Barker DJ, Hales CN *et al.* (1994) Thinness at birth and insulin resistance in
672 adult life. *Diabetologia* **37**, 150-154.

- 673 56. Holemans K, Aerts L, Van Assche FA (2003) Fetal growth restriction and consequences
674 for the offspring in animal models. *J Soc Gynecol Investig* **10**, 392-399.
675

For Review Only

676 **Table 1. Maternal organ weights and gene expression**

	High LA (18% Fat)	High LA (36% Fat)	Low LA (18% Fat)	Low LA (36% Fat)
Bodyweight (g)	308.75 ± 9.82	288.73 ± 14.95	303.29 ± 11.11	302.23 ± 7.85
Heart (% BW)	0.35 ± 0.01	0.36 ± 0.01	0.35 ± 0.01	0.35 ± 0.01
Lungs (% BW) ^a	0.45 ± 0.02	0.51 ± 0.04	0.42 ± 0.02	0.48 ± 0.02
Kidney (% BW)	0.78 ± 0.02	0.83 ± 0.03	0.82 ± 0.02	0.79 ± 0.02
Liver (% BW)	5.01 ± 0.10	4.80 ± 0.28	5.28 ± 0.10	4.88 ± 0.09
Brain (% BW)	0.59 ± 0.02	0.59 ± 0.02	0.58 ± 0.02	0.59 ± 0.02
Gonadal Fat (% BW)	1.88 ± 0.35	2.02 ± 0.39	1.65 ± 0.19	1.61 ± 0.11
Retroperitoneal Fat (% BW)	0.76 ± 0.13	0.76 ± 0.13	0.76 ± 0.08	0.85 ± 0.15
Liver mRNA Expression				
<i>Fasn</i> ^{a*}	20.98 ± 6.17	7.03 ± 1.26	25.08 ± 8.12	9.45 ± 1.63
<i>Lpl</i>	0.20 ± 0.04	0.19 ± 0.04	0.19 ± 0.04	0.13 ± 0.01
<i>Pparg</i>	0.63 ± 0.22	0.78 ± 0.18	0.41 ± 0.09	0.70 ± 0.16
<i>Srebf1</i>	3.52 ± 0.91	2.56 ± 0.64	7.85 ± 2.57	3.39 ± 0.61
Gonadal Fat mRNA Expression				
<i>Fasn</i> ^{a*}	1.29 ± 0.64	0.18 ± 0.05	2.50 ± 1.16	0.37 ± 0.14
<i>Lpl</i>	0.90 ± 0.23	0.87 ± 0.06	1.56 ± 0.41	1.48 ± 0.46
<i>Ppparg</i>	0.91 ± 0.23	1.22 ± 0.20	1.12 ± 0.13	1.16 ± 0.18
<i>Srebf1</i>	1.80 ± 0.48	1.56 ± 0.31	3.43 ± 1.16	2.21 ± 0.62
<i>Lep</i>	0.49 ± 0.08	1.00 ± 0.29	1.10 ± 0.31	1.38 ± 0.25

677 All values are mean ± SEM and n=6-9 per dietary group. The effect of dietary fatty acid ratio
678 and dietary fat content were assessed using a two-way ANOVA. ^a indicates a significant
679 effect of dietary fat content (P<0.05, *P<0.01). [Although not statistically significant there](#)
680 [was some evidence that maternal Srebf1 expression was influenced by the LA \(P=0.08\) and](#)
681 [fat content \(P=0.06\) of the diet.](#)

682 **Table 2. Birth outcomes**

	High LA (18% Fat)	High LA (36% Fat)	Low LA (18% Fat)	Low LA (36% Fat)
n	6	8	7	9
Litter Size	12.83 ± 1.19	13.00 ± 1.21	13.14 ± 0.40	13.33 ± 1.08
Sex Ratio (<u>male/female</u>)	1.01 ± 0.23	0.97 ± 0.24	1.27 ± 0.28	1.13 ± 0.26
Male Birthweight (g) ^a	6.19 ± 0.53	5.19 ± 0.18	5.66 ± 0.14	5.36 ± 0.11
Female Birthweight (g) ^a	5.60 ± 0.37	4.85 ± 0.21	5.26 ± 0.14	5.07 ± 0.12

683 All values are mean ± SEM. The effect of dietary fatty acid ratio and dietary fat content was
684 assessed using a two-way ANOVA. ^a indicates a significant effect of maternal dietary fat
685 content (P<0.05).

686 **Table 3. Offspring organ weights and hepatic gene expression**

Experimental Group	Male				Female			
	High LA (18% Fat)	High LA (36% Fat)	Low LA (18% Fat)	Low LA (36% Fat)	High LA (18% Fat)	High LA (36% Fat)	Low LA (18% Fat)	Low LA (36% Fat)
1 Week Offspring								
Bodyweight (g)	17.52 ± 1.22 ^a	12.85 ± 1.16 ^b	16.61 ± 0.41 ^a	14.20 ± 0.63 ^b	15.79 ± 1.11 ^a	12.44 ± 1.17 ^b	15.66 ± 0.66 ^a	13.40 ± 0.56 ^b
Heart (% BW)	0.59 ± 0.07	0.67 ± 0.06	0.58 ± 0.04	0.64 ± 0.02	0.56 ± 0.02 ^a	0.70 ± 0.06 ^b	0.57 ± 0.06 ^a	0.69 ± 0.04 ^b
Lungs (% BW)	1.87 ± 0.05	1.73 ± 0.04	1.89 ± 0.05	1.90 ± 0.06	1.96 ± 0.11	1.92 ± 0.05	1.88 ± 0.12	1.93 ± 0.05
Kidney (%BW)	1.27 ± 0.08	1.34 ± 0.05	1.19 ± 0.09	1.22 ± 0.02	1.25 ± 0.04	1.38 ± 0.06	1.21 ± 0.10	1.26 ± 0.03
Liver (% BW)	3.17 ± 0.16 ^a	3.39 ± 0.13 ^a	2.81 ± 0.12 ^b	2.89 ± 0.09 ^b	3.18 ± 0.10	3.20 ± 0.27	2.96 ± 0.13	2.99 ± 0.05
Liver <i>Fasn</i>	0.21 ± 0.08 ^a	0.24 ± 0.05 ^b	0.18 ± 0.02 ^a	0.38 ± 0.04 ^b	0.15 ± 0.02 ^a	0.22 ± 0.03 ^a	0.32 ± 0.06 ^b	0.35 ± 0.08 ^b
Liver <i>Lpl</i>	1.09 ± 0.38 ^a	1.26 ± 0.25 ^b	0.76 ± 0.15 ^a	2.01 ± 0.38 ^b	1.26 ± 0.24	1.37 ± 0.46	1.59 ± 0.28	1.81 ± 0.35
Liver <i>Pparg</i>	0.40 ± 0.16	0.30 ± 0.07	0.46 ± 0.14	0.38 ± 0.08	0.51 ± 0.11	0.52 ± 0.13	0.62 ± 0.16	0.41 ± 0.06
Liver <i>Srebp1</i>	0.63 ± 0.16	0.56 ± 0.09	0.51 ± 0.10	0.74 ± 0.10	0.44 ± 0.06 ^a	0.44 ± 0.05 ^a	0.64 ± 0.11 ^b	0.80 ± 0.12 ^b
2 Week Offspring								
Bodyweight (g)	39.76 ± 1.67 ^a	31.78 ± 2.17 ^b	39.89 ± 0.59 ^a	31.56 ± 1.49 ^b	37.77 ± 1.55 ^a	31.70 ± 2.05 ^b	38.49 ± 0.93 ^a	30.75 ± 1.29 ^b
Heart (% BW)	0.60 ± 0.01	0.60 ± 0.02	0.61 ± 0.03	0.63 ± 0.01	0.67 ± 0.06	0.67 ± 0.01	0.65 ± 0.03	0.61 ± 0.02
Lungs (% BW)	1.33 ± 0.20	1.26 ± 0.05	1.25 ± 0.07	1.42 ± 0.07	1.28 ± 0.07	1.32 ± 0.05	1.26 ± 0.08	1.32 ± 0.06
Kidney (%BW)	1.05 ± 0.02	1.02 ± 0.03	1.06 ± 0.02	1.00 ± 0.03	1.17 ± 0.04	1.15 ± 0.04	1.14 ± 0.01	1.05 ± 0.02
Gonadal Fat (%BW)	0.22 ± 0.06	0.18 ± 0.02	0.19 ± 0.02	0.18 ± 0.01	0.24 ± 0.02	0.21 ± 0.02	0.23 ± 0.02	0.24 ± 0.03
Retroperitoneal Fat (%BW)	0.36 ± 0.01	0.41 ± 0.04	0.41 ± 0.02	0.39 ± 0.02	0.33 ± 0.03	0.27 ± 0.02	0.29 ± 0.03	0.27 ± 0.01
Liver (% BW)	3.01 ± 0.06	3.08 ± 0.14	3.11 ± 0.02	3.03 ± 0.02	3.18 ± 0.09	3.15 ± 0.09	3.23 ± 0.05	3.01 ± 0.10
Liver <i>FAS</i> <i>Fasn</i>	0.17 ± 0.01	0.18 ± 0.02	0.19 ± 0.02	0.20 ± 0.02	0.19 ± 0.02	0.20 ± 0.03	0.22 ± 0.03	0.24 ± 0.03
Liver <i>LPL</i> <i>Lpl</i>	1.70 ± 0.25 ^a	1.81 ± 0.29 ^b	1.60 ± 0.13 ^a	2.44 ± 0.23 ^b	1.25 ± 0.16	1.89 ± 0.16	2.01 ± 0.29	1.81 ± 0.08
Liver <i>PPARγ</i> <i>Pparg</i>	0.56 ± 0.17	0.66 ± 0.10	0.48 ± 0.10	0.42 ± 0.07	0.79 ± 0.25 ^a	0.58 ± 0.07 ^a	0.31 ± 0.06 ^b	0.43 ± 0.07 ^b
Liver <i>SREBP1e</i> <i>Srebp1</i>	0.74 ± 0.02	0.71 ± 0.08	0.83 ± 0.06	0.80 ± 0.05	0.68 ± 0.07 ^a	0.68 ± 0.05 ^a	0.83 ± 0.06 ^b	0.95 ± 0.10 ^b

687 All values are mean ± SEM. A two-way ANOVA was used to analyse results with maternal dietary fatty acid ratio and maternal dietary fat

688 content as factors. Different superscripts denote values which are significantly different (P<0.05). n=4-9 per dietary group. All comparisons are

689 made within sex group.

690 **Table 4. Offspring liver composition**

Experimental Group	Male				Female			
	High LA (18% Fat)	High LA (36% Fat)	Low LA (18% Fat)	Low LA (36% Fat)	High LA (18% Fat)	High LA (36% Fat)	Low LA (18% Fat)	Low LA (36% Fat)
1 Week Offspring								
Liver DNA ($\mu\text{g}/\text{mg}$ tissue)	0.48 \pm 0.06	0.54 \pm 0.04	0.56 \pm 0.06	0.52 \pm 0.03	0.51 \pm 0.03	0.51 \pm 0.04	0.50 \pm 0.04	0.52 \pm 0.02
Liver Protein (mg/g tissue)	119.2 \pm 12.8	137.7 \pm 8.9	135.6 \pm 5.2	129.8 \pm 4.9	123.8 \pm 4.5	138.8 \pm 8.3	128.6 \pm 3.3	129.5 \pm 5.2
Liver Glycogen ($\mu\text{g}/\text{mg}$ tissue)	12.71 \pm 0.70 ^a	11.26 \pm 1.86 ^a	9.72 \pm 1.32 ^b	8.64 \pm 0.76 ^b	9.70 \pm 0.89	7.73 \pm 0.88	9.00 \pm 1.43	11.27 \pm 1.80
2 Week Offspring								
Liver DNA ($\mu\text{g}/\text{mg}$ tissue)	0.59 \pm 0.03	0.53 \pm 0.05	0.56 \pm 0.04	0.51 \pm 0.03	0.52 \pm 0.02 ^a	0.61 \pm 0.05 ^b	0.52 \pm 0.03 ^a	0.57 \pm 0.01 ^b
Liver Protein (mg/g tissue)	115.1 \pm 3.6	129.9 \pm 13.5	130.2 \pm 10.0	117.9 \pm 9.4	117.2 \pm 9.7	132.3 \pm 9.1	120.7 \pm 9.4	120.6 \pm 6.5
Liver Glycogen ($\mu\text{g}/\text{mg}$ tissue)	9.45 \pm 0.61	7.48 \pm 0.54	8.35 \pm 0.98	9.30 \pm 1.75	-	-	-	-

691 All values are mean \pm SEM. A two-way ANOVA was used to analyse results with maternal dietary fatty acid ratio and maternal dietary fat
692 content as factors. Different superscripts denote values which are significantly different ($P < 0.05$). n=4-9 per dietary group. All comparisons are
693 made within sex group.

694 **Figures**

695

696 **Figure 1.** Maternal average daily (A) feed intake, (B) energy intake and (C) protein intake
697 during pre-feeding, pregnancy and lactation fed on either a high LA (18% fat) diet (closed
698 circles), high LA (36% fat) diet (open circles), low LA (18% fat) diet (closed squares) and a
699 low LA (36% fat) diet (open squares). Values are means \pm SEM and n=6-9 per group. The
700 effects of dietary fatty acid ratio and dietary fat content were determined using a two-way
701 repeated measures ANOVA. * indicates a significant effect of dietary fat content (** P<0.01,
702 *** P<0.001). † indicates a significant interaction between dietary fat content and fatty acid
703 ratio.

704

705 **Figure 2.** Maternal whole blood fatty acids profile at (A/B) baseline (C/D) after 4 weeks on
706 experimental diet and (D/E) at the end of lactation (3 weeks post-partum). Values are means
707 \pm SEM and n=6-9 per group. The effects of dietary fatty acid ratio and dietary fat content
708 were determined using a two-way ANOVA (*P<0.05, **P<0.01, ***P<0.001). † indicates a
709 significant interaction effect (P<0.05).

710

711 **Figure 3.** Offspring whole blood fatty acids profile at (A/B) one week of age and (C/D) at
712 two weeks of age. Values are means \pm SEM and n=11-17 per group. The effects of maternal
713 dietary fatty acid ratio, maternal dietary fat content and sex were determined using a three-
714 way ANOVA. No effect of sex was found for any of the fatty acids measured and so male
715 and female samples were combined for further analysis. * Indicates significant difference
716 (*P<0.05, **P<0.01, ***P<0.001). † indicates a significant interaction effect (P<0.05).

Figure 1.




Figure 2.





Figure 3.



The ARRIVE Guidelines Checklist

Animal Research: Reporting In Vivo Experiments

Carol Kilkenny¹, William J Browne², Innes C Cuthill³, Michael Emerson⁴ and Douglas G Altman⁵

¹The National Centre for the Replacement, Refinement and Reduction of Animals in Research, London, UK, ²School of Veterinary Science, University of Bristol, Bristol, UK, ³School of Biological Sciences, University of Bristol, Bristol, UK, ⁴National Heart and Lung Institute, Imperial College London, UK, ⁵Centre for Statistics in Medicine, University of Oxford, Oxford, UK.

	ITEM	RECOMMENDATION	Section/ Paragraph
Title	1	Provide as accurate and concise a description of the content of the article as possible.	
Abstract	2	Provide an accurate summary of the background, research objectives, including details of the species or strain of animal used, key methods, principal findings and conclusions of the study.	
INTRODUCTION			
Background	3	a. Include sufficient scientific background (including relevant references to previous work) to understand the motivation and context for the study, and explain the experimental approach and rationale. b. Explain how and why the animal species and model being used can address the scientific objectives and, where appropriate, the study's relevance to human biology.	
Objectives	4	Clearly describe the primary and any secondary objectives of the study, or specific hypotheses being tested.	
METHODS			
Ethical statement	5	Indicate the nature of the ethical review permissions, relevant licences (e.g. Animal [Scientific Procedures] Act 1986), and national or institutional guidelines for the care and use of animals, that cover the research.	
Study design	6	For each experiment, give brief details of the study design including: <ol style="list-style-type: none"> The number of experimental and control groups. Any steps taken to minimise the effects of subjective bias when allocating animals to treatment (e.g. randomisation procedure) and when assessing results (e.g. if done, describe who was blinded and when). The experimental unit (e.g. a single animal, group or cage of animals). A time-line diagram or flow chart can be useful to illustrate how complex study designs were carried out.	
Experimental procedures	7	For each experiment and each experimental group, including controls, provide precise details of all procedures carried out. For example: <ol style="list-style-type: none"> How (e.g. drug formulation and dose, site and route of administration, anaesthesia and analgesia used [including monitoring], surgical procedure, method of euthanasia). Provide details of any specialist equipment used, including supplier(s). When (e.g. time of day). Where (e.g. home cage, laboratory, water maze). Why (e.g. rationale for choice of specific anaesthetic, route of administration, drug dose used). 	
Experimental animals	8	<ol style="list-style-type: none"> Provide details of the animals used, including species, strain, sex, developmental stage (e.g. mean or median age plus age range) and weight (e.g. mean or median weight plus weight range). Provide further relevant information such as the source of animals, international strain nomenclature, genetic modification status (e.g. knock-out or transgenic), genotype, health/immune status, drug or test naïve, previous procedures, etc. 	

The ARRIVE guidelines. Originally published in *PLoS Biology*, June 2010¹

Housing and husbandry	9	Provide details of: a. Housing (type of facility e.g. specific pathogen free [SPF]; type of cage or housing; bedding material; number of cage companions; tank shape and material etc. for fish). b. Husbandry conditions (e.g. breeding programme, light/dark cycle, temperature, quality of water etc for fish, type of food, access to food and water, environmental enrichment). c. Welfare-related assessments and interventions that were carried out prior to, during, or after the experiment.	
Sample size	10	a. Specify the total number of animals used in each experiment, and the number of animals in each experimental group. b. Explain how the number of animals was arrived at. Provide details of any sample size calculation used. c. Indicate the number of independent replications of each experiment, if relevant.	
Allocating animals to experimental groups	11	a. Give full details of how animals were allocated to experimental groups, including randomisation or matching if done. b. Describe the order in which the animals in the different experimental groups were treated and assessed.	
Experimental outcomes	12	Clearly define the primary and secondary experimental outcomes assessed (e.g. cell death, molecular markers, behavioural changes).	
Statistical methods	13	a. Provide details of the statistical methods used for each analysis. b. Specify the unit of analysis for each dataset (e.g. single animal, group of animals, single neuron). c. Describe any methods used to assess whether the data met the assumptions of the statistical approach.	
RESULTS			
Baseline data	14	For each experimental group, report relevant characteristics and health status of animals (e.g. weight, microbiological status, and drug or test naïve) prior to treatment or testing. (This information can often be tabulated).	
Numbers analysed	15	a. Report the number of animals in each group included in each analysis. Report absolute numbers (e.g. 10/20, not 50% ²). b. If any animals or data were not included in the analysis, explain why.	
Outcomes and estimation	16	Report the results for each analysis carried out, with a measure of precision (e.g. standard error or confidence interval).	
Adverse events	17	a. Give details of all important adverse events in each experimental group. b. Describe any modifications to the experimental protocols made to reduce adverse events.	
DISCUSSION			
Interpretation/scientific implications	18	a. Interpret the results, taking into account the study objectives and hypotheses, current theory and other relevant studies in the literature. b. Comment on the study limitations including any potential sources of bias, any limitations of the animal model, and the imprecision associated with the results ² . c. Describe any implications of your experimental methods or findings for the replacement, refinement or reduction (the 3Rs) of the use of animals in research.	
Generalisability/translation	19	Comment on whether, and how, the findings of this study are likely to translate to other species or systems, including any relevance to human biology.	
Funding	20	List all funding sources (including grant number) and the role of the funder(s) in the study.	

References:

1. Kilkeny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research. *PLoS Biol* 8(6): e1000412. doi:10.1371/journal.pbio.1000412
2. Schulz KF, Altman DG, Moher D, the CONSORT Group (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 340:c332. Cambridge University Press